<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00066</drugbank-id>
  <drugbank-id>BTD00099</drugbank-id>
  <drugbank-id>BTD00064</drugbank-id>
  <drugbank-id>BIOD00099</drugbank-id>
  <drugbank-id>BIOD00064</drugbank-id>
  <drugbank-id>DB09024</drugbank-id>
  <name>Follitropin</name>
  <description>Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO). The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. Follitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).  Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable. However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels. Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH.</description>
  <cas-number>146479-72-3</cas-number>
  <unii>2M2GGL7HUP</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A109</ref-id>
        <pubmed-id>18020563</pubmed-id>
        <citation>Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).</indication>
  <pharmacodynamics>Used for the treatment of female infertility, Follitropin beta or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Follitropin beta is the primary hormone responsible for follicular recruitment and development.</pharmacodynamics>
  <mechanism-of-action>Follitropin is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.</mechanism-of-action>
  <toxicity>Headaches, ovarian cysts, nausea and upper respiratory tract infections occurred in more than 10% of women in clinical trials. In men, the most serious adverse events reported were testicular surgery for cryptorchidism which existed prestudy, hemoptysis, an infected pilonidal cyst, and lymphadenopathy associated with an Epstein-Barr viral infection. Other concerns include overstimulation of the ovaries, pulmonary and vascular complications and multiple births. Post-marketing reports revealed hypersensitivity reactions including anaphylactoid reactions and asthma. Follitropin is contraindicated in pregnant women. No studies have been done in nursing mothers.</toxicity>
  <metabolism/>
  <absorption>The absorption rate is the main driving force behind the pharmokinetics of Follitropin alpha as the rate of absorption was found to be slower than the elimination rate after administration subcutaneously and intramuscularly. The bioavailability is approximately 66-76%. The time to peak after subcutaneous injection in healthy volunteers was 8-16 hours in females and 11-20 hours in males.</absorption>
  <half-life>Circulation half life of 3-4 hours, elimination half life of 35-40 hours</half-life>
  <protein-binding/>
  <route-of-elimination>Via liver and kidneys.</route-of-elimination>
  <volume-of-distribution>* 8 L [female subjects following intravenous administration of a 300 IU dose]</volume-of-distribution>
  <clearance>* 0.01 1*h-1kg-1 [European women with a single intramuscular dose of 300 IU]&#13;
* 0.01 1*h-1kg-1 [Japanese women with a single intramuscular dose of 300 IU]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="">Folitropina alfa</synonym>
    <synonym language="spanish" coder="">Folitropina beta</synonym>
    <synonym language="spanish" coder="">Folitropina delta</synonym>
    <synonym language="english" coder="">Follicle stimulating hormone</synonym>
    <synonym language="english" coder="">Follitrophin alfa</synonym>
    <synonym language="english" coder="">Follitrophin alpha</synonym>
    <synonym language="english" coder="">Follitrophin beta</synonym>
    <synonym language="english" coder="">Follitropin alfa</synonym>
    <synonym language="english" coder="">Follitropin alfa/beta</synonym>
    <synonym language="english" coder="">Follitropin alpha</synonym>
    <synonym language="english" coder="">Follitropin beta</synonym>
    <synonym language="english" coder="">Follitropin delta</synonym>
    <synonym language="english" coder="">Follitropin gamma</synonym>
    <synonym language="english" coder="">Follotropin recombinant</synonym>
    <synonym language="english" coder="">FSH</synonym>
    <synonym language="english" coder="">FSH alpha</synonym>
    <synonym language="english" coder="">FSH-a</synonym>
    <synonym language="english" coder="">FSH-b</synonym>
    <synonym language="english" coder="">FSH-beta</synonym>
    <synonym language="english" coder="">Recombinant human follicle stimulating hormone beta</synonym>
    <synonym language="english" coder="">Recombinant human follicle-stimulating hormone (r-HFSH)</synonym>
    <synonym language="english" coder="">rFSH-alpha</synonym>
  </synonyms>
  <products>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/001</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.125ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/002</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.25ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/003</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.375ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/004</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.50ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/005</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 IU/0.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/006</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.125ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/007</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.125ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/008</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.25ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/010</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.375ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/011</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.375ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/012</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.50ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/013</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.50ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/014</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 IU/0.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/015</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 IU/0.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bemfola Needles</name>
      <labeller>Gedeon Richter Plc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002615</ema-product-code>
      <ema-ma-number>EU/1/13/909/009</ema-ma-number>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.25ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Bravelle</name>
      <labeller>Ferring Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55566-8505</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-05-06</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>75 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021289</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/001</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/002</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/003</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/004</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/005</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/006</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/007</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/008</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/009</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/010</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/011</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/012</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/013</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/014</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/015</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/016</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.18mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/017</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.36mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/018</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>600 IU/0.72mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fertavid</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/001042</ema-product-code>
      <ema-ma-number>EU/1/09/510/019</ema-ma-number>
      <started-marketing-on>2009-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 IU/1.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Follistim</name>
      <labeller>Organon USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-09-29</started-marketing-on>
      <ended-marketing-on>2005-01-01</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>NDA020582</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-23</started-marketing-on>
      <ended-marketing-on>2007-05-23</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>175 [iU]/0.210mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>350 [iU]/0.42mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021211</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>650 [iU]/0.78mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021211</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>975 [iU]/1.17mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021211</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-28</started-marketing-on>
      <ended-marketing-on>2016-06-22</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 [iU]/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>BLA021273</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Follistim AQ</name>
      <labeller>Organon USA Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0052-0309</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-28</started-marketing-on>
      <ended-marketing-on>2016-06-22</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 [iU]/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>BLA021273</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/005</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>75 IU</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/021</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1050 IU/1.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/025</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>75 IU</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/026</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>75 IU</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/027</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>75 IU</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/031</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>450 IU/0.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/032</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>300 IU/0.5ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/033</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.5ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/034</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 IU/0.75ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/035</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 IU/1.5ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-9030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>450 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA020378</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-9070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1050 [iU]/2mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA020378</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-F</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000071</ema-product-code>
      <ema-ma-number>EU/1/95/001/036</ema-ma-number>
      <started-marketing-on>1995-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248154</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>5.5 mcg</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248156</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-30</started-marketing-on>
      <ended-marketing-on>2020-02-28</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>33 mcg</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248157</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-12-30</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>77 mcg</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231464</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-07-25</started-marketing-on>
      <ended-marketing-on>2003-12-29</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>75 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231465</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-07-25</started-marketing-on>
      <ended-marketing-on>2013-08-09</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>150 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243004</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-01-11</started-marketing-on>
      <ended-marketing-on>2003-07-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>37.5 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-f</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02244787</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-11-23</started-marketing-on>
      <ended-marketing-on>2013-08-09</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1200 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-F Pen</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270382</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-F Pen</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270390</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-F Pen</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270404</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonal-F Rff</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-9005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>75 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021765</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Pen</name>
      <labeller>Emd Serono</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1113</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 [iU]/0.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Pen</name>
      <labeller>Emd Serono</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1112</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 [iU]/0.75mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Pen</name>
      <labeller>Emd Serono</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on>2016-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 [iU]/1.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Redi-ject</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 [iU]/0.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Redi-ject</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 [iU]/0.75mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Redi-ject</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 [iU]/1.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gonal-f RFF Redi-ject</name>
      <labeller>EMD Serono, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>44087-1118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-25</started-marketing-on>
      <ended-marketing-on>2019-11-25</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 [iU]/0.25mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021684</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humegon Inj 75 I.U.</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01958992</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2006-08-17</ended-marketing-on>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Menopur</name>
      <labeller>Ferring Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55566-7501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA021663</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ovaleap</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002608</ema-product-code>
      <ema-ma-number>EU/1/13/871/001</ema-ma-number>
      <started-marketing-on>2013-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ovaleap</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002608</ema-product-code>
      <ema-ma-number>EU/1/13/871/002</ema-ma-number>
      <started-marketing-on>2013-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>450 IU/0.75mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Ovaleap</name>
      <labeller>Teva Pharma B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002608</ema-product-code>
      <ema-ma-number>EU/1/13/871/003</ema-ma-number>
      <started-marketing-on>2013-09-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 IU/1.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergonal 75 I.U.</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00254916</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2007-05-07</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Serono Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/001</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Serono Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/002</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Serono Europe Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/003</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/004</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/005</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Merck Europe B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000714</ema-product-code>
      <ema-ma-number>EU/1/07/396/006</ema-ma-number>
      <started-marketing-on>2007-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02445301</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470640</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470659</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470667</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/017</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/018</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/019</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>50 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/020</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/021</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/022</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>75 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/023</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/024</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/025</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/026</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/027</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/028</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/029</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/030</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/031</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/032</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/033</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/034</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>225 IU/0.5mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/038</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 IU/0.36mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/039</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>600 IU/0.72mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/040</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 IU/0.18mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Sharp &amp; Dohme B.V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000086</ema-product-code>
      <ema-ma-number>EU/1/96/008/041</ema-ma-number>
      <started-marketing-on>1996-05-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>900 IU/1.08mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242439</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-24</started-marketing-on>
      <ended-marketing-on>2019-09-30</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242441</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-24</started-marketing-on>
      <ended-marketing-on>2020-07-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243948</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon (600 Iu)</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243949</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-18</started-marketing-on>
      <ended-marketing-on>2005-07-07</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon 100 I.U.</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231656</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-08</started-marketing-on>
      <ended-marketing-on>2006-08-17</ended-marketing-on>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Puregon 50 I.U.</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231655</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-08</started-marketing-on>
      <ended-marketing-on>2006-08-17</ended-marketing-on>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/001</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/002</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/003</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/004</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/005</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003994</ema-product-code>
      <ema-ma-number>EU/1/16/1150/006</ema-ma-number>
      <started-marketing-on>2016-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02474077</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02474085</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02474093</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02487462</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02487470</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Rekovelle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02487489</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Repronex</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-7185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-08-27</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>NDA021047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Cinnal-F</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Fertavid</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola Needles</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bemfola</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Ovaleap</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Ovaleap</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Ovaleap</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Follistim</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Repronex</name>
      <ingredients>Follitropin + Luteinizing hormone</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F Rff</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Redi-ject</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Redi-ject</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Redi-ject</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f RFF Redi-ject</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Menopur</name>
      <ingredients>Follitropin + Luteinizing hormone</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Bravelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Follistim AQ</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-F Pen</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Humegon Inj 75 I.U.</name>
      <ingredients>Follitropin + Luteinizing hormone + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Pergonal 75 I.U.</name>
      <ingredients>Follitropin + Luteinizing hormone</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon (600 Iu)</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Gonal-f</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Puregon 50 I.U.</name>
      <ingredients>Follitropin + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Puregon 100 I.U.</name>
      <ingredients>Follitropin + Sodium chloride</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
    <mixture>
      <name>Rekovelle</name>
      <ingredients>Follitropin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>EMD Canada Inc.</name>
      <url>http://www.emdcanada.com</url>
    </packager>
    <packager>
      <name>Organon Pharmaceuticals</name>
      <url>http://www.organonshop.com</url>
    </packager>
    <packager>
      <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
      <url>http://www.vetter-pharma.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Organon usa inc</manufacturer>
    <manufacturer generic="false" url="">Emd serono inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Follistim aq 75 unit vial</description>
      <cost currency="USD">109.51</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Gonal-f rff 75 unit vial</description>
      <cost currency="USD">117.47</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Follistim aq 150 unit vial</description>
      <cost currency="USD">219.02</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Follistim aq 300 unit cartridge</description>
      <cost currency="USD">438.05</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Follistim AQ 300unt/0.36ml Solution 0.42ml Cartridge</description>
      <cost currency="USD">455.57</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Gonal-f rff 300 unit pen</description>
      <cost currency="USD">469.87</cost>
      <unit>pen</unit>
    </price>
    <price>
      <description>Gonal-f rff 450 unit pen</description>
      <cost currency="USD">704.81</cost>
      <unit>pen</unit>
    </price>
    <price>
      <description>Gonal-f 450 unit Solution Vial</description>
      <cost currency="USD">733.0</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Follistim AQ 600unt/0.72ml Solution 0.78ml Cartridge</description>
      <cost currency="USD">911.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Follistim AQ 900unt/1.08ml Solution 1 Cartridge = 1.17ml</description>
      <cost currency="USD">1366.71</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Gonal-f rff 900 unit pen</description>
      <cost currency="USD">1409.62</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chorionic Gonadotropin</category>
      <mesh-id>D006063</mesh-id>
    </category>
    <category>
      <category>Follicle Stimulating Hormone</category>
      <mesh-id>D005640</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropins</category>
      <mesh-id>D006062</mesh-id>
    </category>
    <category>
      <category>Gonadotropins and Antigonadotropins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropins, Pituitary</category>
      <mesh-id>D006065</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones</category>
      <mesh-id>D010907</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones, Anterior</category>
      <mesh-id>D010908</mesh-id>
    </category>
    <category>
      <category>Placental Hormones</category>
      <mesh-id>D010926</mesh-id>
    </category>
    <category>
      <category>Pregnancy Proteins</category>
      <mesh-id>D011257</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Sex Hormones and Modulators of the Genital System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyroid Products</category>
      <mesh-id>D013972</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 IU/0.25ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>225 IU/3.75ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>225 IU/0.375ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU/0.50ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>450 IU/0.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>75 IU/0.125ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>150 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 [iU]/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 [iU]/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>175 [iU]/0.210mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>350 [iU]/0.42mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>650 [iU]/0.78mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>975 [iU]/1.17mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route/>
      <strength>150 iu</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route/>
      <strength>75 iu</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>150 iu/0.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>225 iu/0.45mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>300 iu/0.6mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>75 iu/0.15mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>150 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>75 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route/>
      <strength>1050 IU/1.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>37.5 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>1050 IU/1.75ML</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>150 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>300 IU/0.5ML</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>37.5 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>450 IU/0.75ML</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>1050 IU/1.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>450 IU/0.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>900 IU/1.5ml</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength>1050 [iU]/2mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength>450 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>1200 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>33 mcg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>37.5 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>5.5 mcg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>77 mcg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>1050 iu/1.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>150 iu</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>300 iu/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>37.5 iu</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>450 iu/0.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>450 iu/0.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 iu</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>900 iu/1.5ml</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength>75 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 [iU]/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>450 [iU]/0.75mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>900 [iU]/1.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 [iU]/0.25mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>22 mcg/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 iu</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form/>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>1200 iu/1ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 iu</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>600 iu/1ml</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>150 iu</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU/0.48ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>900 IU/1.44ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 UI</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>450 UI</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>900 UI</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>150 IU</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>150 UI</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route/>
      <strength>437.5 iu/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 iu/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 iu/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>50 iu/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 iu/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>200 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>225 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>250 IU/0.5ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>300 IU/0.36ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>50 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>600 IU/0.72ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 IU/0.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 IU/0.18mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 IU/0.36mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>600 IU/0.72mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>900 IU/1.08mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>150 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>50 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Parenteral</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Parenteral</route>
      <strength>150 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>400 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>300 IU/0.36ml</strength>
    </dosage>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension</form>
      <route>Parenteral</route>
      <strength>50 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>600 IU/0.72ml</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Parenteral</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Parenteral</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>900 IU/1.08ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>833 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>50 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Cutaneous; Parenteral</route>
      <strength>36 MCG/1.08ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Cutaneous; Parenteral</route>
      <strength>72 MCG/2.16ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>12 MCG/0.36ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>36 MCG/1.08ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>12 mcg/0.36mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>36 mcg/1.08ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>72 mcg/2.16ml</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>33.3 mcg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G03GA06">
      <level code="G03GA">Gonadotropins</level>
      <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03GA10">
      <level code="G03GA">Gonadotropins</level>
      <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="G03GA05">
      <level code="G03GA">Gonadotropins</level>
      <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:18.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00066.pdf?1265922798</fda-label>
  <patents>
    <patent>
      <number>5270057</number>
      <country>United States</country>
      <approved>1993-12-14</approved>
      <expires>2011-03-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2037884</number>
      <country>Canada</country>
      <approved>2003-10-21</approved>
      <expires>2011-03-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7563763</number>
      <country>United States</country>
      <approved>2009-07-21</approved>
      <expires>2019-08-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5929028</number>
      <country>United States</country>
      <approved>1999-07-27</approved>
      <expires>2018-01-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7446090</number>
      <country>United States</country>
      <approved>2008-11-04</approved>
      <expires>2019-08-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7741268</number>
      <country>United States</country>
      <approved>2010-06-22</approved>
      <expires>2024-04-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The risk or severity of adverse effects can be increased when Phentermine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The risk or severity of adverse effects can be increased when Midodrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylephrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The risk or severity of adverse effects can be increased when Metaraminol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Epinephrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The risk or severity of adverse effects can be increased when Dobutamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Benzphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The risk or severity of adverse effects can be increased when Ritodrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The risk or severity of adverse effects can be increased when Diethylpropion is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The risk or severity of adverse effects can be increased when Fenoterol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The risk or severity of adverse effects can be increased when Ephedrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The risk or severity of adverse effects can be increased when Mephentermine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The risk or severity of adverse effects can be increased when Procaterol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The risk or severity of adverse effects can be increased when Clenbuterol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The risk or severity of adverse effects can be increased when MMDA is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The risk or severity of adverse effects can be increased when Midomafetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of adverse effects can be increased when Nylidrin is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The risk or severity of adverse effects can be increased when Tetryzoline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of adverse effects can be increased when Tyramine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The risk or severity of adverse effects can be increased when Etilefrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The risk or severity of adverse effects can be increased when Synephrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The risk or severity of adverse effects can be increased when Racepinephrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The risk or severity of adverse effects can be increased when Ritobegron is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of adverse effects can be increased when Tramazoline is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The risk or severity of adverse effects can be increased when Mephedrone is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of adverse effects can be increased when Fenozolone is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The risk or severity of adverse effects can be increased when Tretoquinol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The risk or severity of adverse effects can be increased when Gepefrine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The risk or severity of adverse effects can be increased when Prenalterol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of adverse effects can be increased when Mefenorex is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of adverse effects can be increased when Labetalol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of adverse effects can be increased when Acebutolol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of adverse effects can be increased when Celiprolol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The risk or severity of adverse effects can be increased when Bucindolol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of adverse effects can be increased when Epanolol is combined with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02058</drugbank-id>
      <name>3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02424</drugbank-id>
      <name>Geldanamycin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Geldanamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02567</drugbank-id>
      <name>PD173955</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with PD173955.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03758</drugbank-id>
      <name>Radicicol</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Radicicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04849</drugbank-id>
      <name>Cediranib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Cediranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04879</drugbank-id>
      <name>Vatalanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05424</drugbank-id>
      <name>Canertinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Tandutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05575</drugbank-id>
      <name>Motesanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06302</drugbank-id>
      <name>Glesatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06469</drugbank-id>
      <name>Lestaurtinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Lestaurtinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08399</drugbank-id>
      <name>Piceatannol</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Piceatannol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08875</drugbank-id>
      <name>Cabozantinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Cabozantinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11689</drugbank-id>
      <name>Selumetinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Selumetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11697</drugbank-id>
      <name>Pacritinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Pacritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11703</drugbank-id>
      <name>Acalabrutinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Acalabrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Icotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11832</drugbank-id>
      <name>Crenolanib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Crenolanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11904</drugbank-id>
      <name>Flumatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11973</drugbank-id>
      <name>Tesevatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Fostamatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12048</drugbank-id>
      <name>Savolitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12307</drugbank-id>
      <name>Foretinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Foretinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12323</drugbank-id>
      <name>Radotinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Radotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Larotrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12978</drugbank-id>
      <name>Pexidartinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Pexidartinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11652</drugbank-id>
      <name>Tucatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Tucatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11791</drugbank-id>
      <name>Capmatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15685</drugbank-id>
      <name>Selpercatinib</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Selpercatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00609</drugbank-id>
      <name>Ethionamide</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Ethionamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Resorcinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be decreased when used in combination with Follitropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dosulepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Opipramol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine oxide.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
    <sequence format="FASTA">&gt;Beta chain
NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET
VRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>55 °C</value>
      <source>Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.330</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.50</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>22672.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C975H1513N267O304S26</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11463</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11457</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22944</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7649</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508818</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M16647</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449693</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01225</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001028</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Follicle-stimulating_hormone</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201692</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>227518</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/follitrop.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/follitropin-alfa-powder.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000387</id>
      <name>Follicle-stimulating hormone receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A2011</ref-id>
            <pubmed-id>11299519</pubmed-id>
            <citation>Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10.</citation>
          </article>
          <article>
            <ref-id>A2013</ref-id>
            <pubmed-id>7755615</pubmed-id>
            <citation>Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9.</citation>
          </article>
          <article>
            <ref-id>A2014</ref-id>
            <pubmed-id>2108722</pubmed-id>
            <citation>Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200.</citation>
          </article>
          <article>
            <ref-id>A2017</ref-id>
            <pubmed-id>8319832</pubmed-id>
            <citation>Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46.</citation>
          </article>
          <article>
            <ref-id>A2019</ref-id>
            <pubmed-id>8070368</pubmed-id>
            <citation>Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40.</citation>
          </article>
          <article>
            <ref-id>A109</ref-id>
            <pubmed-id>18020563</pubmed-id>
            <citation>Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P23945" source="Swiss-Prot">
        <name>Follicle-stimulating hormone receptor</name>
        <general-function>G-protein coupled peptide receptor activity</general-function>
        <specific-function>Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.</specific-function>
        <gene-name>FSHR</gene-name>
        <locus>2p21-p16</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>367-387
399-421
444-465
486-508
529-550
574-597
609-630</transmembrane-regions>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>7.19</theoretical-pi>
        <molecular-weight>78264.07</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3969</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FSHR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M65085</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182771</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>253</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>253</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23945</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FSHR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Follitropin receptor</synonym>
          <synonym>FSH-R</synonym>
          <synonym>LGR1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037007|Follicle-stimulating hormone receptor
MALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV
IQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP
NLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN
GIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN
LKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE
VDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM
GYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS
VDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK
VQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL
AFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP
LITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS
TVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)
ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT
CGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT
CCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC
ATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT
GATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT
AGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC
AACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG
ATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT
GAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT
GGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA
AGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA
GTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT
CTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG
CTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC
TGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA
GTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC
AGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA
GTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG
GGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC
ATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT
ATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA
GTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA
GGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG
ACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG
GTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT
GCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG
GATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG
GCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC
ATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT
GACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC
CTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT
GCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG
CTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC
ACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT
GGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
          <pfam>
            <identifier>PF01462</identifier>
            <name>LRRNT</name>
          </pfam>
          <pfam>
            <identifier>PF13306</identifier>
            <name>LRR_5</name>
          </pfam>
          <pfam>
            <identifier>PF12369</identifier>
            <name>GnHR_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>follicle-stimulating hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled peptide receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female gamete generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>follicle-stimulating hormone signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>primary ovarian follicle growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spermatogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>uterus development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>